(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback